- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-p53-S20 AntibodyPeptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP3199a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-p53-S20 Antibody - Product info | |
| Application | WB, IHC
|
| Primary Accession | P04637 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 43653 Da |
Phospho-p53-S20 Antibody - Additional info | |
| Gene ID 7157 | |
| Other Names TP53; P53; Cellular tumor antigen p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53 | |
| Target/Specificity This Phospho-p53-S20 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S20 of human p53. | |
| Dilution WB~~1:100~500WB~~1:1000 IHC~~1:50~100 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein G affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with control and phosphorylated peptides. The phospho-specific antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Phospho-p53-S20 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
Phospho-p53-S20 Antibody - Protein Information | |
| Name TP53 | |
| Synonyms P53 | |
| Function Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; te function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA- Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis | |
| Cellular Location Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2. Translocates to mitochondria upon oxidative stress Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli | |
| Tissue Location Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine | |
Phospho-p53-S20 Antibody - Related products
AP2505b: p53 Antibody (Sumoylation Site Specific)
AP3199a: Phospho-p53-S20 Antibody
AP3200a: Phospho-p53-S315 Antibody
AP3201a: Phospho-P53-S33 Antibody
AP3202a: Phospho-P53-S37 Antibody
AP3203a: Phospho-p53-S376 Antibody
AP3204a: Phospho-p53-S378 Antibody
AP3206a: Phospho-P53-S9 Antibody
AP3207a: Phospho-p53-T18 Antibody
AP3491a: Phospho-p53-S46 Antibody
AP3492a: Phospho-p53-T55 Antibody
AP6266b: p53 Antibody (C-term)
BP3199a: Phospho-p53-S20 Antibody Blocking Peptide
BP3200a: Phospho-p53-S315 Antibody Blocking Peptide
BP3201a: Phospho-P53-S33 Antibody Blocking Peptide
BP3202a: Phospho-P53-S37 Antibody Blocking Peptide
BP3203a: Phospho-p53-S376 Antibody Blocking Peptide
BP3204a: Phospho-p53-S378 Antibody Blocking Peptide
BP3206a: Phospho-P53-S9 Antibody Blocking Peptide
BP3207a: Phospho-p53-T18 Antibody Blocking Peptide
BP3491a: Phospho-p53-S46 Antibody Blocking Peptide
BP3492a: Phospho-p53-T55 Antibody Blocking Peptide
BP6266b: p53 Antibody (C-term) Blocking Peptide
BP6266d: p53 Antibdoy (T55) Blocking Peptide
BP6266e: p53 Antibdoy (S15) Blocking Peptide
BP6266f: p53 Antibody (S37) Blocking Peptide
BP6266g: p53 Antibody (S46) Blocking Peptide
BP6266h: p53 Antibody (S315) Blocking Peptide
AT4310a: TP53 Antibody (monoclonal) (M01)
AJ1573b: p53 Antibody (C-term)
AJ1573c: p53 Antibody (N-term)
AJ1573d: p53 Antibody Acetyl (K382)
AJ1573e: p53 Antibody Acetyl (K373)
AJ1573f: p53 Antibody Phospho (pS33)
AJ1573g: p53 Antibody Phospho (pS392)
AJ1573h: p53 Antibody Phospho (pS392)
AJ1573i: p53 Antibody Phospho (pS46)
Phospho-p53-S20 Antibody - Application data
-
Western blot analysis of anti-hp53 Pab (Cat. #AP3199a) in A2058 cell line lysate. hp53(arrow) was detected using the purified Pab.
-
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
Phospho-p53-S20 Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Tumor protein p53, a nuclear protein, plays an essential role in the regulation of cell cycle, specifically in the transition from G0 to G1. It is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing DNA-binding, oligomerization and transcription activation domains. It is postulated to bind as a tetramer to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome.
REFERENCES
Garden, G.A., et al., Biochem. Biophys. Res. Commun. 331(3):799-809 (2005). Castedo, M., et al., Biochem. Biophys. Res. Commun. 331(3):701-706 (2005). Duensing, A., et al., Biochem. Biophys. Res. Commun. 331(3):694-700 (2005). Seemann, S., et al., Oncogene 24(24):3853-3863 (2005). Mann, K., et al., Oncogene 24(24):3964-3975 (2005).